Autoinjectors are easy-to-handle and cost-effective medical
devices that can be used by patients, caregivers, and even untrained personnel
to deliver a dose of a particular drug. Autoinjectors are used by patients to
manage autoimmune diseases and chronic diseases. They are used for a wide range
of indications such as rheumatoid arthritis, multiple sclerosis, diabetes, and
anaphylaxis.
Request Research Sample Pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=173991724
According to the new market research report Autoinjectors
Market by Therapy (Rheumatoid Arthritis, Multiple Sclerosis, Anaphylaxis,
Cardiovascular Diseases, Diabetes), Type (Disposable, Reusable), Route of
administration (Subcutaneous, Intramuscular), End User (Hospital) - Global
Forecast to 2025" The global autoinjectors market is projected to reach
USD 104.9 billion by 2025 from USD 46.0 billion in 2020, at a CAGR of 17.9%
from 2020 to 2025. The key factors driving the growth of this market include
the growing prevalence of targeted therapies such as rheumatoid arthritis and
multiple sclerosis, rising incidence of anaphylaxis, and increasing number of
regulatory approvals.
Diabetes segment is expected to show the highest growth
in the forecast period.
The autoinjectors market, by therapy, is segmented into rheumatoid arthritis, multiple sclerosis, anaphylaxis, diabetes, multiple sclerosis, and other therapies (includes cardiovascular diseases, migraine treatment, anemia, and progesterone therapy). Diabetes mellitus, commonly known as diabetes, is a disease that arises from the insufficient production of insulin or the body’s inability to utilize insulin. To maintain healthy blood glucose levels, diabetes patients need a daily intake of insulin or Glucagon-like peptide-1 (GLP-1). This scenario will provide companies with abundant opportunities to develop innovative solutions and cater the end user’s demand.
Disposable autoinjectors accounted for the largest share
of the autoinjectors market in 2020.
Based on type, the autoinjectors market is segmented into
reusable and disposable autoinjectors. In 2019, the disposable autoinjectors
segment accounted for the largest share of the global autoinjectors market.
Disposable autoinjectors are the most-preferred autoinjectors due to their ease
of use and the presence of a built-in glass syringe (eliminates the need of
manually loading the glass syringe), which makes it more convenient for
patients with reduced dexterity or visual impairment.
Home care settings segment accounted for the largest
share and is expected to show the highest growth in the forecast period.
Based on end users, the autoinjectors market is segmented
into home care settings, hospitals & clinics, and ambulatory care settings.
Of all these end-user segments, home care settings accounted for the largest
share of the autoinjectors market in 2019. The large share of this end-user
segment can primarily be attributed to the rapid growth in the geriatric
population across the globe and the growing need for cost-effective drug
administration.
Asia Pacificis projected to witness highest CAGR during
the forecast period of 2020–2025.
Geographically, the autoinjectors market is segmented into
North America, Europe, the Asia Pacific, Latin America, and Middle East &
Africa. Growth in the Asia Pacific market is majorly driven by the large
diabetes population and increasing healthcare expenditure which has drawn a
number of major autoinjector device manufacturers to this region. These companies
are increasing their presence in the Asia Pacific market through several
approaches, such as establishing sales offices and partnering with local
pharmaceutical companies.
The prominent players in this market are AbbVie Inc. (US), Mylan (US), Eli Lilly and Company (US), Ypsomed (Switzerland), Amgen (US), Becton, Dickinson and Company (US), GlaxoSmithKline plc (UK), Johnson & Johnson (US), Teva Pharmaceutical (Israel), Antares Pharma (US), Merck KGaA (Germany).
Recent Developments
·
Antares Pharma (US) signed an agreement with
Lunatus Global Medical Supplies (Dubai). In this agreement, Antares will supply
packaged products to Lunatus and Lunatus will submit and obtain regulatory
approval for XYOSTED in the UAE and Saudi Arabia as well as promote, market,
and distribute XYOSTED in these two countries.
·
SHL Medical (Switzerland) acquired Weibel CDS
(Switzerland). This acquisition aimed at strengthening SHL Medical’s ability to
provide more advanced drug delivery systems based on human-centered designs and
functionality.
·
Eli Lilly invested USD 470 million and created
over 460 new jobs in Durham, NC. This expansion brought a new state-of-the-art
pharmaceutical manufacturing facility to North Carolina’s research triangle
park.
·
Becton, Dickinson and Company (US) launched a
disposable autoinjector namely BD Intevia 1ml Disposable Autoinjector. This
activity will strengthen company’s autoinjector’s portfolio.